# Incyte Corp: overview

INCY · Nasdaq · CIK 879169 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/incy.md) · [Financials](/companies/incy/financials.md) · [Filings](/companies/incy/filings.md) · [Insiders](/companies/incy/insiders.md)

Latest reported revenue: [$1.56bn](/filings/0000879169-26-000066.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000879169-26-000066).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,179 d](/filings/0000879169-26-000010.md) | [1,053](/filings/0000879169-26-000026.md) | [1,216](/filings/0000879169-26-000056.md) | [1,366](/filings/0000879169-26-000066.md) | [1,507 d](/filings/0000879169-26-000010.md) | [1,273](/filings/0000879169-26-000026.md) | [1,674](/filings/0000879169-26-000056.md) | [1,557](/filings/0000879169-26-000066.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [25.6% d](/filings/0000879169-26-000010.md) | [19.5%](/filings/0000879169-26-000026.md) | [43.6%](/filings/0000879169-26-000056.md) | [32.5%](/filings/0000879169-26-000066.md) | [22.3% d](/filings/0000879169-26-000010.md) | [23.7%](/filings/0000879169-26-000026.md) | [41.7%](/filings/0000879169-26-000056.md) | [(45.5%)](/filings/0000879169-26-000066.md) |
| Net margin | % | [17.1% d](/filings/0000879169-26-000010.md) | [15.0%](/filings/0000879169-26-000066.md) | [33.3%](/filings/0000879169-26-000066.md) | [31.1%](/filings/0000879169-26-000066.md) | [19.9% d](/filings/0000879169-26-000010.md) | [23.8%](/filings/0000879169-26-000066.md) | [35.0%](/filings/0000879169-26-000066.md) | [(50.4%)](/filings/0000879169-26-000066.md) |
| Diluted EPS | $ per share | not reported | [0.80](/filings/0000879169-26-000026.md) | [2.04](/filings/0000879169-26-000056.md) | [2.11](/filings/0000879169-26-000066.md) | not reported | [1.47](/filings/0000879169-26-000026.md) | [2.81](/filings/0000879169-26-000056.md) | [(3.86)](/filings/0000879169-26-000066.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,986](/filings/0000879169-24-000045.md) | [3,395](/filings/0001628280-25-004633.md) | [3,696](/filings/0000879169-26-000010.md) | [4,241](/filings/0000879169-26-000010.md) | [5,141](/filings/0000879169-26-000010.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [19.6%](/filings/0000879169-24-000045.md) | [17.1%](/filings/0001628280-25-004633.md) | [16.8%](/filings/0000879169-26-000010.md) | [1.4%](/filings/0000879169-26-000010.md) | [29.5%](/filings/0000879169-26-000010.md) |
| Net margin | % | [31.8%](/filings/0000879169-24-000045.md) | [10.0%](/filings/0001628280-25-004633.md) | [16.2%](/filings/0000879169-26-000010.md) | [0.8%](/filings/0000879169-26-000010.md) | [25.0%](/filings/0000879169-26-000010.md) |
| Diluted EPS | $ per share | [4.27](/filings/0000879169-24-000045.md) | [1.52](/filings/0001628280-25-004633.md) | [2.65](/filings/0000879169-26-000010.md) | [0.15](/filings/0000879169-26-000010.md) | [6.41](/filings/0000879169-26-000010.md) |
| Free cash flow | $m | [568](/filings/0000879169-24-000045.md) | [892](/filings/0001628280-25-004633.md) | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/incy/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $3.49bn | 30,762,330 |  | Added +17,918 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.04bn | 18,032,718 |  | Reduced −945,480 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $1.36bn | 11,957,326 |  | Reduced −295,030 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.25bn | 11,024,289 |  | Added +94,223 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.10bn | 9,722,336 |  | Added +80,952 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $883.2m | 7,791,091 |  | Added +31,908 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $603.2m | 5,320,901 |  | Reduced −487,029 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $536.5m | 4,750,735 |  | Added +47,551 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $462.6m | 4,080,461 |  | Added +209,697 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $405.3m | 3,575,521 |  | Added +309,385 |

## Recent filings

[All 2,021 filings](/companies/incy/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:03 ET | [10-Q](/filings/0000879169-26-000066.md) | Quarterly report, period 2026-09-30 | 0000879169-26-000066 |
| 2026-10-29 | 07:03 ET | [8-K](/filings/0000879169-26-000063.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000879169-26-000063 |
| 2026-08-31 | 16:29 ET | [8-K](/filings/0000879169-26-000058.md) | 8.01 Other events | 0000879169-26-000058 |
| 2026-07-28 | 16:02 ET | [10-Q](/filings/0000879169-26-000056.md) | Quarterly report, period 2026-06-30 | 0000879169-26-000056 |
| 2026-07-28 | 07:02 ET | [8-K](/filings/0000879169-26-000053.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000879169-26-000053 |
| 2026-07-06 | 16:06 ET | [8-K](/filings/0000879169-26-000048.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000879169-26-000048 |
| 2026-06-22 | 07:00 ET | [8-K](/filings/0000879169-26-000046.md) | 8.01 Other events | 0000879169-26-000046 |
| 2026-06-09 | 16:06 ET | [8-K](/filings/0000879169-26-000043.md) | 5.07 Shareholder vote results | 0000879169-26-000043 |
| 2026-06-08 | 07:05 ET | [8-K](/filings/0000879169-26-000040.md) | 8.01 Other events | 0000879169-26-000040 |
| 2026-05-11 | 16:59 ET | [SCHEDULE 13D/A](/filings/0001104659-26-058726.md) | Ownership report, active investor, amended | 0001104659-26-058726 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000879169-26-000010.md), filed Feb 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 879169
- Tickers: INCY
- Exchange: Nasdaq
- SIC code: 8731 Services-Commercial Physical & Biological Research
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:38 ET. No prices; not investment advice.